Global Recombinant Human Coagulation Factor IX Market Growth 2025-2031

Publication ID:

LPI08256102

Publication Date:

August 8, 2025

Pages:

110

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Recombinant Human Coagulation Factor IX market size is predicted to grow from US$ 574 million in 2025 to US$ 716 million in 2031; it is expected to grow at a CAGR of 3.7% from 2025 to 2031.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Recombinant human coagulation factor IX is a drug produced by genetic recombination technology, mainly used to treat hemophilia B (i.e. congenital coagulation factor IX deficiency). Its function is to supplement the coagulation factor IX that is lacking in the patient's body to help control and prevent bleeding. The drug is a colorless and clear solution after reconstitution. It is suitable for daily bleeding management and perioperative management of hemophilia B patients, but is not suitable for the treatment of other types of coagulation factor deficiency or conditions related to the anticoagulant effect of coumarin.
United States market for Recombinant Human Coagulation Factor IX is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Recombinant Human Coagulation Factor IX is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Recombinant Human Coagulation Factor IX is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Recombinant Human Coagulation Factor IX players cover Grifols, Biogen, Octapharma, Baxter, Cusabio, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
The 鈥淩ecombinant Human Coagulation Factor IX Industry Forecast鈥� looks at past sales and reviews total world Recombinant Human Coagulation Factor IX sales in 2024, providing a comprehensive analysis by region and market sector of projected Recombinant Human Coagulation Factor IX sales for 2025 through 2031. With Recombinant Human Coagulation Factor IX sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Recombinant Human Coagulation Factor IX industry.
This Insight Report provides a comprehensive analysis of the global Recombinant Human Coagulation Factor IX landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Recombinant Human Coagulation Factor IX portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Recombinant Human Coagulation Factor IX market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Recombinant Human Coagulation Factor IX and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Recombinant Human Coagulation Factor IX.
This report presents a comprehensive overview, market shares, and growth opportunities of Recombinant Human Coagulation Factor IX market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
250 IU/Bottle
500 IU/Bottle
1000 IU/Bottle
2000 IU/Bottle
Segmentation by Application:
Adult Patients
Child Patients
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Grifols
Biogen
Octapharma
Baxter
Cusabio
Sanofi
Cayman
NovoPro Bioscience
Sino Biological
Bio-Techne
IDELVION
Hualan Bio
Shuyang
ChinaBiologic
Diagbio
Key Questions Addressed in this Report
What is the 10-year outlook for the global Recombinant Human Coagulation Factor IX market?
What factors are driving Recombinant Human Coagulation Factor IX market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Recombinant Human Coagulation Factor IX market opportunities vary by end market size?
How does Recombinant Human Coagulation Factor IX break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Recombinant Human Coagulation Factor IX Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Recombinant Human Coagulation Factor IX by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Recombinant Human Coagulation Factor IX by Country/Region, 2020, 2024 & 2031
2.2 Recombinant Human Coagulation Factor IX Segment by Type
2.2.1 250 IU/Bottle
2.2.2 500 IU/Bottle
2.2.3 1000 IU/Bottle
2.2.4 2000 IU/Bottle
2.3 Recombinant Human Coagulation Factor IX Sales by Type
2.3.1 Global Recombinant Human Coagulation Factor IX Sales Market Share by Type (2020-2025)
2.3.2 Global Recombinant Human Coagulation Factor IX Revenue and Market Share by Type (2020-2025)
2.3.3 Global Recombinant Human Coagulation Factor IX Sale Price by Type (2020-2025)
2.4 Recombinant Human Coagulation Factor IX Segment by Application
2.4.1 Adult Patients
2.4.2 Child Patients
2.5 Recombinant Human Coagulation Factor IX Sales by Application
2.5.1 Global Recombinant Human Coagulation Factor IX Sale Market Share by Application (2020-2025)
2.5.2 Global Recombinant Human Coagulation Factor IX Revenue and Market Share by Application (2020-2025)
2.5.3 Global Recombinant Human Coagulation Factor IX Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Recombinant Human Coagulation Factor IX Breakdown Data by Company
3.1.1 Global Recombinant Human Coagulation Factor IX Annual Sales by Company (2020-2025)
3.1.2 Global Recombinant Human Coagulation Factor IX Sales Market Share by Company (2020-2025)
3.2 Global Recombinant Human Coagulation Factor IX Annual Revenue by Company (2020-2025)
3.2.1 Global Recombinant Human Coagulation Factor IX Revenue by Company (2020-2025)
3.2.2 Global Recombinant Human Coagulation Factor IX Revenue Market Share by Company (2020-2025)
3.3 Global Recombinant Human Coagulation Factor IX Sale Price by Company
3.4 Key Manufacturers Recombinant Human Coagulation Factor IX Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Recombinant Human Coagulation Factor IX Product Location Distribution
3.4.2 Players Recombinant Human Coagulation Factor IX Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 World Historic Review for Recombinant Human Coagulation Factor IX by Geographic Region
4.1 World Historic Recombinant Human Coagulation Factor IX Market Size by Geographic Region (2020-2025)
4.1.1 Global Recombinant Human Coagulation Factor IX Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Recombinant Human Coagulation Factor IX Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Recombinant Human Coagulation Factor IX Market Size by Country/Region (2020-2025)
4.2.1 Global Recombinant Human Coagulation Factor IX Annual Sales by Country/Region (2020-2025)
4.2.2 Global Recombinant Human Coagulation Factor IX Annual Revenue by Country/Region (2020-2025)
4.3 Americas Recombinant Human Coagulation Factor IX Sales Growth
4.4 APAC Recombinant Human Coagulation Factor IX Sales Growth
4.5 Europe Recombinant Human Coagulation Factor IX Sales Growth
4.6 Middle East & Africa Recombinant Human Coagulation Factor IX Sales Growth
5 Americas
5.1 Americas Recombinant Human Coagulation Factor IX Sales by Country
5.1.1 Americas Recombinant Human Coagulation Factor IX Sales by Country (2020-2025)
5.1.2 Americas Recombinant Human Coagulation Factor IX Revenue by Country (2020-2025)
5.2 Americas Recombinant Human Coagulation Factor IX Sales by Type (2020-2025)
5.3 Americas Recombinant Human Coagulation Factor IX Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Recombinant Human Coagulation Factor IX Sales by Region
6.1.1 APAC Recombinant Human Coagulation Factor IX Sales by Region (2020-2025)
6.1.2 APAC Recombinant Human Coagulation Factor IX Revenue by Region (2020-2025)
6.2 APAC Recombinant Human Coagulation Factor IX Sales by Type (2020-2025)
6.3 APAC Recombinant Human Coagulation Factor IX Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Recombinant Human Coagulation Factor IX by Country
7.1.1 Europe Recombinant Human Coagulation Factor IX Sales by Country (2020-2025)
7.1.2 Europe Recombinant Human Coagulation Factor IX Revenue by Country (2020-2025)
7.2 Europe Recombinant Human Coagulation Factor IX Sales by Type (2020-2025)
7.3 Europe Recombinant Human Coagulation Factor IX Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Recombinant Human Coagulation Factor IX by Country
8.1.1 Middle East & Africa Recombinant Human Coagulation Factor IX Sales by Country (2020-2025)
8.1.2 Middle East & Africa Recombinant Human Coagulation Factor IX Revenue by Country (2020-2025)
8.2 Middle East & Africa Recombinant Human Coagulation Factor IX Sales by Type (2020-2025)
8.3 Middle East & Africa Recombinant Human Coagulation Factor IX Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Recombinant Human Coagulation Factor IX
10.3 Manufacturing Process Analysis of Recombinant Human Coagulation Factor IX
10.4 Industry Chain Structure of Recombinant Human Coagulation Factor IX
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Recombinant Human Coagulation Factor IX Distributors
11.3 Recombinant Human Coagulation Factor IX Customer
12 World Forecast Review for Recombinant Human Coagulation Factor IX by Geographic Region
12.1 Global Recombinant Human Coagulation Factor IX Market Size Forecast by Region
12.1.1 Global Recombinant Human Coagulation Factor IX Forecast by Region (2026-2031)
12.1.2 Global Recombinant Human Coagulation Factor IX Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Recombinant Human Coagulation Factor IX Forecast by Type (2026-2031)
12.7 Global Recombinant Human Coagulation Factor IX Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 Grifols
13.1.1 Grifols Company Information
13.1.2 Grifols Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
13.1.3 Grifols Recombinant Human Coagulation Factor IX Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Grifols Main Business Overview
13.1.5 Grifols Latest Developments
13.2 Biogen
13.2.1 Biogen Company Information
13.2.2 Biogen Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
13.2.3 Biogen Recombinant Human Coagulation Factor IX Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Biogen Main Business Overview
13.2.5 Biogen Latest Developments
13.3 Octapharma
13.3.1 Octapharma Company Information
13.3.2 Octapharma Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
13.3.3 Octapharma Recombinant Human Coagulation Factor IX Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Octapharma Main Business Overview
13.3.5 Octapharma Latest Developments
13.4 Baxter
13.4.1 Baxter Company Information
13.4.2 Baxter Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
13.4.3 Baxter Recombinant Human Coagulation Factor IX Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Baxter Main Business Overview
13.4.5 Baxter Latest Developments
13.5 Cusabio
13.5.1 Cusabio Company Information
13.5.2 Cusabio Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
13.5.3 Cusabio Recombinant Human Coagulation Factor IX Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Cusabio Main Business Overview
13.5.5 Cusabio Latest Developments
13.6 Sanofi
13.6.1 Sanofi Company Information
13.6.2 Sanofi Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
13.6.3 Sanofi Recombinant Human Coagulation Factor IX Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Sanofi Main Business Overview
13.6.5 Sanofi Latest Developments
13.7 Cayman
13.7.1 Cayman Company Information
13.7.2 Cayman Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
13.7.3 Cayman Recombinant Human Coagulation Factor IX Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Cayman Main Business Overview
13.7.5 Cayman Latest Developments
13.8 NovoPro Bioscience
13.8.1 NovoPro Bioscience Company Information
13.8.2 NovoPro Bioscience Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
13.8.3 NovoPro Bioscience Recombinant Human Coagulation Factor IX Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 NovoPro Bioscience Main Business Overview
13.8.5 NovoPro Bioscience Latest Developments
13.9 Sino Biological
13.9.1 Sino Biological Company Information
13.9.2 Sino Biological Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
13.9.3 Sino Biological Recombinant Human Coagulation Factor IX Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Sino Biological Main Business Overview
13.9.5 Sino Biological Latest Developments
13.10 Bio-Techne
13.10.1 Bio-Techne Company Information
13.10.2 Bio-Techne Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
13.10.3 Bio-Techne Recombinant Human Coagulation Factor IX Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Bio-Techne Main Business Overview
13.10.5 Bio-Techne Latest Developments
13.11 IDELVION
13.11.1 IDELVION Company Information
13.11.2 IDELVION Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
13.11.3 IDELVION Recombinant Human Coagulation Factor IX Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 IDELVION Main Business Overview
13.11.5 IDELVION Latest Developments
13.12 Hualan Bio
13.12.1 Hualan Bio Company Information
13.12.2 Hualan Bio Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
13.12.3 Hualan Bio Recombinant Human Coagulation Factor IX Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 Hualan Bio Main Business Overview
13.12.5 Hualan Bio Latest Developments
13.13 Shuyang
13.13.1 Shuyang Company Information
13.13.2 Shuyang Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
13.13.3 Shuyang Recombinant Human Coagulation Factor IX Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 Shuyang Main Business Overview
13.13.5 Shuyang Latest Developments
13.14 ChinaBiologic
13.14.1 ChinaBiologic Company Information
13.14.2 ChinaBiologic Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
13.14.3 ChinaBiologic Recombinant Human Coagulation Factor IX Sales, Revenue, Price and Gross Margin (2020-2025)
13.14.4 ChinaBiologic Main Business Overview
13.14.5 ChinaBiologic Latest Developments
13.15 Diagbio
13.15.1 Diagbio Company Information
13.15.2 Diagbio Recombinant Human Coagulation Factor IX Product Portfolios and Specifications
13.15.3 Diagbio Recombinant Human Coagulation Factor IX Sales, Revenue, Price and Gross Margin (2020-2025)
13.15.4 Diagbio Main Business Overview
13.15.5 Diagbio Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂